The reduced need for surgical pain relief during the pandemic has forced Tasmanian poppy processor Sun Pharma to cut its growing area for the coming season.
- Sun Pharma has slashed the size of its growing area across Tasmania as global demand for painkillers falls
- Twenty growers in the state’s south will be cut and a further 150 will have their contracts reduced
- Worldwide demand for opium-based pain relief dropped to an all-time low last year as elective surgeries were cancelled
The multinational, which contracts growers across the state to produce poppies for its factory at Latrobe, has also made two field officers redundant as part of the cuts.
Worldwide demand for opium-based pain relief dropped to an all-time low last…